AR027469A1 - Derivados de aminoalcohol - Google Patents

Derivados de aminoalcohol

Info

Publication number
AR027469A1
AR027469A1 ARP010100783A ARP010100783A AR027469A1 AR 027469 A1 AR027469 A1 AR 027469A1 AR P010100783 A ARP010100783 A AR P010100783A AR P010100783 A ARP010100783 A AR P010100783A AR 027469 A1 AR027469 A1 AR 027469A1
Authority
AR
Argentina
Prior art keywords
methoxycarbonylamino
compounds
medicaments
hydrogen
compound
Prior art date
Application number
ARP010100783A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR027469A1 publication Critical patent/AR027469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Se describen compuestos derivados de aminoalcohol de la formula (1) en la cual: R1 es hidrogeno o un grupo protector amino; R2 es hidrogeno o hidroxi; R3 yR4 son, en forma independiente, N-metil-metoxicarbonilamino, N-etil-metoxicarbonilamino, N-prop il-metoxicarbonilamino o 3-etilureido; o R3 y R4 son ambosmetoxicatbonilamino sustituidos en una posicion meta de los anillos de benceno; o una de sus sales, y el compuesto (2) denominado (2S)-1-fenoxi-3-[3,3-bis[4-(metoxicarbonilamino)-fenil]propila mino]-2-propanol sulfato (2:1) y algunas de sus formas cristalinas como agonistas del receptor adrenérgico beta3. También sedescriben las composiciones farmacéuticas que contienen dichos compuestos, la preparacion del compuesto (2) y el uso de tales compuestos para la preparacion demedicamentos o como medicamentos.
ARP010100783A 2000-02-21 2001-02-21 Derivados de aminoalcohol AR027469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ5753A AUPQ575300A0 (en) 2000-02-21 2000-02-21 New compound

Publications (1)

Publication Number Publication Date
AR027469A1 true AR027469A1 (es) 2003-03-26

Family

ID=3819864

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100783A AR027469A1 (es) 2000-02-21 2001-02-21 Derivados de aminoalcohol

Country Status (10)

Country Link
US (1) US20030032834A1 (es)
EP (1) EP1257528A1 (es)
JP (1) JP2003522814A (es)
KR (1) KR20020092947A (es)
CN (1) CN1424999A (es)
AR (1) AR027469A1 (es)
AU (1) AUPQ575300A0 (es)
CA (1) CA2400860A1 (es)
TW (1) TW593240B (es)
WO (1) WO2001060786A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR120400A0 (en) * 2000-11-02 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. New compound
CN101039902B (zh) * 2004-09-21 2010-11-10 安斯泰来制药有限公司 氨基醇衍生物
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
CN109640657B (zh) * 2016-07-07 2020-10-30 美国陶氏益农公司 制备4-烷氧基-3-(酰基或脂族饱和烃基)氧基吡啶甲酰胺的方法
CN114805094B (zh) * 2021-06-03 2024-04-02 上海如鲲新材料股份有限公司 一种双(3-氨基-4-羟基苯基)六氟丙烷的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AUPP549998A0 (en) * 1998-08-26 1998-09-17 Fujisawa Pharmaceutical Co., Ltd. New compound

Also Published As

Publication number Publication date
TW593240B (en) 2004-06-21
WO2001060786A1 (en) 2001-08-23
EP1257528A1 (en) 2002-11-20
CN1424999A (zh) 2003-06-18
JP2003522814A (ja) 2003-07-29
AUPQ575300A0 (en) 2000-03-16
KR20020092947A (ko) 2002-12-12
US20030032834A1 (en) 2003-02-13
CA2400860A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
AR038045A1 (es) Agentes terapeuticos
CA2244773A1 (en) Tropane-derivatives, their preparation and use
AR021354A1 (es) Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica
AR036057A1 (es) Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden
DK1150944T3 (da) N2-phenylamidinderivater
DK0595851T3 (da) Fremgangsmåde til fremstilling af sertralin-mellemprodukter
ES2188957T3 (es) N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
UY26727A1 (es) Derivados de tropano útiles en terapia
AR044694A1 (es) Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
BR9610960A (pt) Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
AR047544A1 (es) Proceso para la preparacion de compuestos de triazol sustituidos
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
AR010080A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
BRPI0602132A (pt) compostos de indanil-piperazina, processo para sua preparação e composições farmacêuticas contendo os mesmos
AR027469A1 (es) Derivados de aminoalcohol
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
SE8107387L (sv) Nya fenylalkylaminer, framstellning derav och anvendning som lekemedel
AR037459A1 (es) Antagonistas vi del receptor ccr-3
AR042404A2 (es) Compuestos derivados de anilina
NO973213L (no) Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse